Moran Susan 4

What Happened
Susan Moran, a director of Crescent BioPharma (CBIO), was granted a derivative award on 2026-06-02 representing the right to purchase 11,050 ordinary shares. The Form 4 reports the acquisition price as $0.00 (total reported value $0), indicating a grant of options/rights rather than an immediate purchase of shares.

Key Details

• Transaction date: 2026-06-02; Form 4 filed: 2026-06-03 (timely file).
• Transaction type/code: Award/Grant of a derivative (Code A).
• Amount: right to purchase 11,050 shares; reported price per share: $0.00.
• Vesting: vests in full on the earlier of (i) June 2, 2027 or (ii) the issuer's next annual meeting of shareholders, subject to continued service (per footnote).
• Shares owned after transaction: not specified in the filing.
• No indication this was an exercise or sale — it’s a grant, not a cashless exercise or disposition.

Context
This is a compensation-style option/award that gives the director the right to buy shares in the future subject to vesting and service conditions. It does not represent immediate stock ownership or a sale, and it shouldn’t be read as an immediate buying or selling signal. If and when the option is exercised, subsequent Form 4s will disclose exercise details and any resulting share ownership.